Key Takeaways
- • Carlyle Group's distributable earnings rose 13.7% year-over-year to $436 million ($1.01 per share) in Q4 2025, driven by private-equity dealmaking, credit gains, and secondaries performance.
- • Net realized performance revenue surged to $123 million in the quarter, fueled by exit activity across the U.S. buyout fund, European technology funds, and an opportunistic credit fund.
- • Assets under management climbed 8% to $477 billion following $53.7 billion in fresh capital raised during fiscal 2025, with inflows concentrated in secondaries (Carlyle AlpInvest) and credit strategies.
- • CEO Harvey Schwartz stated 2025 was a "record year" for Carlyle, with the firm significantly outperforming internal targets, capitalizing on M&A rebound as interest rates fell and policy uncertainty eased.
- • Fee-related earnings increased modestly 1% to $290 million, while notable exits included Ampere Computing and Calastone in 2025, plus the December IPO of medical supplies company Medline.
Summary
Carlyle Group reported strong fourth-quarter profitability on February 6, 2026, with distributable earnings—the metric measuring profits available for shareholder distributions—rising 13.7% year-over-year to $436 million, or $1.01 per share. The performance reflected broad-based strength across the asset manager's core operating segments, particularly its private-equity arm, which generated substantial income through portfolio company exits and realizations.
Net realized performance revenue reached $123 million in the quarter, representing a significant contributor to profitability. This revenue stream benefited from exit activity at Carlyle's U.S. buyout fund, two European technology-focused funds, and an opportunistic credit fund. The timing of these realizations aligned with a broader market recovery in mergers and acquisitions activity during late 2025, as declining interest rates reduced financing costs for dealmakers and initial concerns about U.S. policy impacts under the Trump administration subsided.
CEO Harvey Schwartz characterized 2025 as a "record year" for Carlyle, noting the firm substantially exceeded targets established at year's outset. The company's assets under management expanded to $477 billion, representing an 8% increase year-over-year, supported by $53.7 billion in new capital raised during fiscal 2025. Capital inflows concentrated primarily in two strategically important segments: Carlyle AlpInvest, the secondaries platform trading secondary private-equity stakes in an expanding market, and the firm's credit funds. Fee-related earnings increased 1% to $290 million, reflecting steady management fee generation across the platform.
Carlyle completed several notable portfolio transactions in 2025, including the sale of its stakes in U.S. semiconductor startup Ampere Computing and British fund services network Calastone, while also bringing medical supplies company Medline public in December. These exits demonstrated active portfolio management and liquidity generation for investors across multiple sectors and geographies.
Carlyle's equity performance has been volatile in early 2026, with shares declining approximately 6% year-to-date amid broader market selloffs, though the stock remains up more than 5% over the trailing twelve-month period.
Net realized performance revenue reached $123 million in the quarter, representing a significant contributor to profitability. This revenue stream benefited from exit activity at Carlyle's U.S. buyout fund, two European technology-focused funds, and an opportunistic credit fund. The timing of these realizations aligned with a broader market recovery in mergers and acquisitions activity during late 2025, as declining interest rates reduced financing costs for dealmakers and initial concerns about U.S. policy impacts under the Trump administration subsided.
CEO Harvey Schwartz characterized 2025 as a "record year" for Carlyle, noting the firm substantially exceeded targets established at year's outset. The company's assets under management expanded to $477 billion, representing an 8% increase year-over-year, supported by $53.7 billion in new capital raised during fiscal 2025. Capital inflows concentrated primarily in two strategically important segments: Carlyle AlpInvest, the secondaries platform trading secondary private-equity stakes in an expanding market, and the firm's credit funds. Fee-related earnings increased 1% to $290 million, reflecting steady management fee generation across the platform.
Carlyle completed several notable portfolio transactions in 2025, including the sale of its stakes in U.S. semiconductor startup Ampere Computing and British fund services network Calastone, while also bringing medical supplies company Medline public in December. These exits demonstrated active portfolio management and liquidity generation for investors across multiple sectors and geographies.
Carlyle's equity performance has been volatile in early 2026, with shares declining approximately 6% year-to-date amid broader market selloffs, though the stock remains up more than 5% over the trailing twelve-month period.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.